Semler Scientific Files 8-K
| Field | Detail |
|---|---|
| Company | Semler Scientific, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 24, 2025 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing, sec
TL;DR
SEMLER SCIENTIFIC FILED AN 8-K ON 9/23/25 - DETAILS PENDING
AI Summary
Semler Scientific, Inc. filed an 8-K on September 23, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about the nature of these events or financial statements, only that they are being reported.
Why It Matters
This 8-K filing indicates that Semler Scientific has reported significant events or financial updates to the SEC, which could impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without specific negative or positive disclosures, making the immediate risk level low.
Key Players & Entities
- Semler Scientific, Inc. (company) — Registrant
- September 23, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 51 E Campbell Ave , Suite 107-D Campbell , CA 95008 (address) — Principal executive offices
FAQ
What specific "Other Events" are being reported by Semler Scientific, Inc. in this 8-K filing?
The filing does not specify the nature of the "Other Events" beyond listing the item information.
What are the "Financial Statements and Exhibits" that Semler Scientific, Inc. is reporting?
The filing lists "Financial Statements and Exhibits" as an item information but does not provide details on their content.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 23, 2025.
What is the principal executive office address for Semler Scientific, Inc.?
The principal executive office is located at 51 E Campbell Ave, Suite 107-D, Campbell, CA 95008.
What is Semler Scientific, Inc.'s fiscal year end?
Semler Scientific, Inc.'s fiscal year ends on December 31.
Filing Stats: 2,181 words · 9 min read · ~7 pages · Grade level 16.9 · Accepted 2025-09-23 19:31:24
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share SMLR The Nasdaq
Filing Documents
- tm2526607d5_8k.htm (8-K) — 46KB
- tm2526607d5_ex99-1.htm (EX-99.1) — 202KB
- tm2526607d5_ex99-2.htm (EX-99.2) — 637KB
- 0001104659-25-092624.txt ( ) — 1144KB
- smlr-20250923.xsd (EX-101.SCH) — 3KB
- smlr-20250923_lab.xml (EX-101.LAB) — 33KB
- smlr-20250923_pre.xml (EX-101.PRE) — 22KB
- tm2526607d5_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events As previously disclosed, on September 22, 2025, Semler Scientific, Inc., or Semler Sci, and Strive, Inc., or Strive, entered into an Agreement and Plan of Merger, or the Merger Agreement, providing for the acquisition of Semler Sci by Strive in an all-stock transaction subject to the terms and conditions set forth in the Merger Agreement. Semler Sci is filing this current report on Form 8-K to provide certain supplemental disclosures regarding Strive in Exhibit 99.1 hereto, as well as supplemental unaudited pro forma combined consolidated financial information as of and at June 30, 2025 and December 31, 2024 in Exhibit 99.2 hereto, which information is incorporated by reference herein. Cautionary Statement Regarding Forward-Looking Statements Certain statements herein and the documents incorporated herein by reference may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended, and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the outlook and expectations of Strive and Semler Sci, respectively, with respect to the proposed transaction, the strategic benefits and financial benefits of the proposed transaction, including the expected impact of the proposed transaction on the combined company's future financial performance, the timing of the closing of the proposed transaction, and the ability to successfully integrate the combined businesses. Such "could," "should," "would," "believe," "contemplate," "expect," "estimate," "continue," "plan,"
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed with this report: Exhibit No. Description 99.1 Supplemental information regarding Strive, Inc. dated September 22, 2025. 99.2 Supplemental unaudited pro forma combined consolidated financial information. 104 The cover page from this current report on Form 8-K, formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SEMLER SCIENTIFIC, INC. Date: September 23, 2025 By: /s/ Renae Cormier Name: Renae Cormier Title: Chief Financial Officer ( Principal Financial Officer and Principal Accounting Officer)